Entero Healthcare Solutions Reports Results, Approves Board Changes, and Targets Acquisition of Vishal Surgicals
Entero Healthcare Solutions Limited announced the outcomes of its Board of Directors meeting held on May 25, 2026. The Company approved the audited financial results for the quarter and year ended March 31, 2026, alongside several key governance and strategic actions, including the re-appointment of independent directors and the proposed acquisition of Vishal Surgicals and Vishal Surgicals & Medicals.Governance and Board Approvals
The Board of Directors approved the re-appointment of three independent directors for the second term of five years, effective from August 25, 2026, to August 24, 2031, subject to shareholder approval at the ensuing Annual General Meeting (AGM).The re-appointments include:
- Mr. Sujesh Vasudevan (DIN: 08240092): An alumnus of Harvard Business School with over 20 years of experience in the pharmaceutical industry.
- Mr. Rajesh Shashikant Dalal (DIN: 03504969): A healthcare leader with over 35 years of experience, who previously served as Managing Director of Johnson& Johnson India.
- Ms. Sandhya Gadkari Sharma (DIN: 02005378): Experienced in Banking and Investment, with over four decades in the industry, previously associated with Mahindra and Mahindra Limited and ICICI Bank Limited.
The Company also approved the re-appointment of Ernst & Young LLP (EY) as Internal Auditor for the financial year 2026-27.
Strategic Acquisition
The Board reviewed the acquisition of Vishal Surgicals and Vishal Surgicals & Medicals, a Partnership Firm, through its subsidiary, Sai Pharma Distributors Private Limited, via a Slump Sale / Business Transfer Agreement (BTA).Details regarding the targets and the acquisition plan were disclosed:
- Vishal Surgicals: Turnover in FY 2024-25 was INR 116.06 Million.
- Vishal Surgicals & Medicals: Turnover in FY 2024-25 was INR 57.94 Million.
Financial Results Summary
The Company released audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2026.Consolidated Financial Results (Rs. in Millions)
| Particulars | Quarter ended March 31, 2026 (Audited) | Year ended March 31, 2026 (Audited) |
|---|---|---|
| Total Revenue from Operations | 19,099.27 | 65,912.12 |
| Total Income | 19,139.325 | 1,352.85 |
| Total Expenses | 18,559.88 | 49,965.46 |
| Profit Before Tax | 579.47 | 1,793.36 |
| Total Tax Expenses | 128.19 | 334.96 |
| Profit for the Year | 451.28 | 1,458.40 |
Consolidated Balance Sheet Summary
The consolidated total assets increased significantly, reaching 36,002.63 Million at March 31, 2026, compared to 27,025.15 Million at the same date in the previous year.
| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| Total Non-current Assets | 10,918.27 Million | 6,268.06 Million |
| Total Current Assets | 25,084.36 Million | 20,757.09 Million |
| TOTAL ASSETS | 36,002.63 Million | 27,025.15 Million |
| Total Equity and Liabilities | ||
| Total Equity attributable to Owners of the Company | 16,886.10 Million | 17,241.45 Million |
| Total Non-current Liabilities | 2,601.47 Million | 871.42 Million |
| Total Current Liabilities | 1,875.70 Million | 8,460.17 Million |
| TOTAL LIABILITIES | 18,477.17 Million | 27,025.15 Million |
The Company's total cash and cash equivalents at the end of the year were 1,468.76 Million, compared to 2,292.78 Million in the prior year.
Corporate Actions and General Meetings
The Board approved the allotment of 7,240 Equity Shares of Rs. 10 each to eligible employees upon the exercise of options vested under the Entero Employee Stock Option Plan 2023. Additionally, the Board noted the grant of fresh 7,300 Employee Stock Options.The Company also announced that its 8th Annual General Meeting (AGM) is scheduled for Wednesday, August 19, 2026, at 12:30 p.m. IST, via Video Conferencing /Other-Audio Visual Means.
Financial Highlights Table
For a detailed comparison, the following table summarizes the key figures for the year ended March 31, 2026, versus the previous year.| Metric | Year ended 31 March 2026 (Audited) | Year ended 31 March 2025 (Audited) |
|---|---|---|
| Profit Before Tax | 1,793.36 Million | 1,387.39 Million |
| Total Comprehensive Income | 1,452.49 Million | 1,079.21 Million |
| Total Equity | 16,886.10 Million | 17,241.45 Million |
| Cash and Cash Equivalents | 1,468.76 Million | 2,292.78 Million |
The audit of the standalone and consolidated financial results for the year ended March 31, 2026, was completed by MSKA & Associates LLP.
ENTERO Stock Price Movement
Entero Healthcare Solutions Limited shares today slipped by 3.20% to close at ₹1349.4, falling ₹43.40 from the previous day's close. The equity settled on a volume of 253,087 shares, finishing near the lower end of its intraday trading range.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: